Lupin recently announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.
The FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), the company said in a statement.